New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders

Current Psychiatry Reports

Volumn 18, Issue 7, 2016, Pages

  Dakwar, Elias ^a   Nunes, Edward V ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Addiction; Behavioral treatment; Cannabis; Cocaine; Combined treatment; Medication; Use disorder

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; DESIPRAMINE; DEXAMPHETAMINE; LEVODOPA; METHAMPHETAMINE; PSYCHOTROPIC AGENT;

BEHAVIOR THERAPY; CANNABIS ADDICTION; CLINICAL EFFECTIVENESS; COCAINE DEPENDENCE; COGNITIVE BEHAVIORAL THERAPY; CONTINGENCY MANAGEMENT; HUMAN; REVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME; MULTIMODALITY CANCER THERAPY; PROCEDURES; SUBSTANCE-RELATED DISORDERS;

BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; HUMANS; PSYCHOTROPIC DRUGS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84971283568     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-016-0703-4     Document Type: Review

References (83)

1. Shorter D, Domingo CB, Kosten TR. Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy. Expert Opin Emerg Drug. 2015;20(1):15–29.
2. Copeland J, Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatry. 2009;21(2):96–103.
3. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. Curr Pharm Des. 2011;17(14):1351. Also, NIDA: http://www.drugabuse.gov/publications/research-reports/marijuana/available-treatments-marijuana-use-disorders.
4. Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of Topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481–8.
5. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16(19):2091–7.
6. McLellan AT, Arndt IO, Metzger DS, Woody GE, O’Brlen CP. The effects of psychosocial services in substance abuse treatment. Addict Nurs Netw. 1993;5(2):38–47.
7. Carroll KM, Kosten TR, Rounsaville BJ. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend. 2004;75(2):123–34.
8. Ouimette PC, Moos RH, Finney JW. Influence of outpatient treatment and 12-step group involvement on one-year substance abuse treatment outcomes. J Stud Alcohol. 1998;59(5):513–22.
9. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2006;101(11):1546–60.
10. Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs. 2009;70:516–27.
11. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drugs Alcohol Abuse. 2006;32(4):503–17.
12. Volkow ND, Li TK. Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci. 2004;5(12):963–70.
13. Vanderplasschen W. Contingency management in substance abuse treatment. Addiction. 2008;103(5):857.
14. Stanger C, Ryan SR, Scherer EA, Norton GE, Budney AJ. Clinic-and home-based contingency management plus parent training for adolescent cannabis use disorders. J Am Acad Child Adolesc Psychiatry. 2015.
15. Higgins ST, Silverman K, Heil SH, editors. Contingency management in substance abuse treatment. New York: Guilford Press; 2007.
16. Kirby KC, Benishek LA, Dugosh KL, Kerwin ME. Substance abuse treatment providers’ beliefs and objections regarding contingency management: implications for dissemination. Drug Alcohol Depend. 2006;85(1):19–27.
17. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2014. A good overview of the neural correlates of addictive behavior.
18. Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology. 1999;146(4):373–90.
19. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141(1):105–30.
20. Rooke SE, Hine DW, Thorsteinsson EB. Implicit cognition and substance use: a meta-analysis. Addict Behav. 2008;33(10):1314–28.
21. Bickel WK, Marsch LA. Toward a behavioral economic understanding of drug dependence: delay discounting processes. Addiction. 2001;96(1):73–86.
22. Bates ME, Bowden SC, Barry D. Neurocognitive impairment associated with alcohol use disorders: implications for treatment. Exp Clin Psychopharmacol. 2002;10(3):193.
23. Bowden SC, Crews FT, Bates ME, Fals‐Stewart W, Ambrose ML. Neurotoxicity and neurocognitive impairments with alcohol and drug-use disorders: potential roles in addiction and recovery. Alcohol Clin Exp Res. 2001;25(2):317–21.
24. Jurado MB, Rosselli M. The elusive nature of executive functions: a review of our current understanding. Neuropsychol Rev. 2007;17(3):213–33.
25. Thomas MJ, Kalivas PW, Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol. 2008;154(2):327–42.
26. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol. 2008;75(1):218–65.
27. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol. 1998;12(1):54–67.
28. Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatr. 2002;159(10):1642–52.
29. Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav. 2012;100(4):801–10.
30. Singh M, Keer D, Klimas J, Wood E, Werb D. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized control trials. Addiction. 2016.
31. Schmitz JM, Rathnayaka N, Green CE, Moeller FG, Dougherty AE, Grabowski J. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front Psychiatry. 2012, 3.
32. Torrens M, Fonseca F, Mateu G, Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression: a systematic review and meta-analysis. Drug Alcohol Depend. 2005;78(1):1–22.
33. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681–98.
34. Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, et al. Imaging dopamine transmission in cocaine dependence: response to treatment linked to neurochemistry. Am J Psychiatry. 2011;168(6):634–41. doi:10.1176/appi.ajp.2010.10050748.
35. Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacol Rev. 2014;66(1):193–221.
36. Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2009;101(1–2):34–41.
37. Schmitz JM, Mooney ME, Gerard Moeller F, Stotts AL, Charles G, John G. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008;94(1–3):142–50.
38. Schmitz JM, Lindsay JA, Stotts AL, Green CE, Moeller FG. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets. Exp Clin Psychopharmacol. 2010;18(3):238.
39. Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70(3):315–25.
40. Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63(2):219–28.
41. Moeller FG, Schmitz JM, Steinberg JL, Green CM, Reist C, Lai LY, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse. 2007;33(3):367–78.
42. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):68–77. doi:10.1016/j.tins.2011.11.005.
43. Markou A, Koob GF. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology. 1991;4(1):17–26.
44. Kalivas PW, LaLumiere R, Knackstedt L, Shen H. Glutamate transmission in addiction. Neuropharmacology. 2009;56 suppl 1:169–73.
45. Bisaga A, Aharonovich E, Cheng WY, Levin FR, Mariani JJ, Raby WN, et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend. 2010;111(1–2):97–104.
46. Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry. 2012;72(11):950–6.
47. Reissner KJ, Kalivas PW. Using glutamate homeostasis as a target for treating addictive disorders. Behav Pharmacol. 2010;21(5–6):514.
48. Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, et al. N-Acetylcysteine reverses cocaine-induced metaplasticity. Nat Neurosci. 2009;12:182–9.
49. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatr. 2012;169(8):805–12. This manuscript suggests that NAC might facilitate CM-based approaches for cannabis dependence by normalizing NAcc functioning.
50. LaRowe SD, Kalivas PW, Nicholas JS, Randall PK, Mardikian PN, Malcolm R. A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. Am J Addict. 2013;22(5):443–52.
51. Kadden R. Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence (No. 94). DIANE Publishing;1995.
52. Marlatt GA, Donovan DM, editors. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. New York: Guilford Press; 2005.
53. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT. Understanding and preventing relapse. Am Psychol. 1986;41(7):765.
54. Levin FR, Mariani JJ, Specker S, Mooney M, Mahony A, Brooks DJ., et al. Extended-release mixed amphetamine salts vs placebo for comorbid adult attention-deficit/hyperactivity disorder and cocaine use disorder: a randomized clinical trial. JAMA Psychiatry.2015. This manuscript demonstrates the importance of addressing comorbid vulnerabilities, such as ADHD, to facilitate effective treatment for cocaine use disorders.
55. Wender PH. Attention-deficit hyperactivity disorder in adults. Psychiatr Clin North Am. 1998;21(4):761–74.
56. Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ. Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology. 2006;31(5):1036–47.
57. Skolnick P, Popik P, Trullas P. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30(11):563–9.
58. Zarate Jr C, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry. 2010;18(5):293–303.
59. Monteggia LM, Zarate Jr C. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol. 2015;30C:139–43.
60. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergicneurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17(8):2921–7.
61. Maeng S, Zarate Jr CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptors. Biol Psychiatry. 2008;63:349–52.
62. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;20:959–64.
63. Liu RJ, Lee FS, Li XY, et al. BDNF Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2010;71:996–1005.
64. Belujon P, Jakobowski NL, Dollish HK, Grace AA. Withdrawal from acute amphetamine induces an amygdala-driven attenuation of dopamine neuron activity: reversal by ketamine. Neuropsychopharmacology. 2015.
65. Berglind WJ, See RE, Fuchs RA, et al. A BDNF infusion into the medial prefrontal cortex suppresses cocaine seeking in rats. Eur J Neurosci. 2007;26(3):757–66.
66. Scheidegger M, Walter M, Lehmann M, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One. 2012;7(9):e4479.
67. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65(4):289–95.
68. Hoerst M, Weber-Fahr W, Tunc-Skarka N, Ruf M, Bohus M, Schmahl C, et al. Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch Gen Psychiatry. 2010;67(9):946–54.
69. Kosten TA, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, et al. Cue-induced brain activity changes and relapse in cocaine dependent patients. Neuropsychopharmacology. 2006;31:644–50.
70. Matuskey D, Luo X, Zhang S, et al. Methylphenidate remediates error-preceding activation of the default mode brain regions in cocaine-addicted individuals. Psychiatry Res. 2013;214(2):116–21.
71. Mealing GA, Lanthorn TH, Murray CL, Small DL, Morley P. Differences in degree of trapping of low-affinity noncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. Pharmacol Exp Ther. 1999;288(1):204–10.
72. Dakwar E, Levin FR, Foltin R, Nunes EV, Hart CL. The effect of sub-anesthetic ketamine on motivation to quit and cue-induced craving in cocaine dependent research volunteers. Biol Psychiatry. 2014.
73. Dakwar E, Hart CL, Levin FR, Nunes EV, Foltin RW. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, cross-over trial. Mol Psychiatry. 2016. doi:10.1038/mp.2016.39.
74. Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29(2):165–83.
75. Krupitsky EM, Grineko AY, Berkaliev TN, Paley AI, Tetrov UN, Mushkov KA, et al. The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method. Alcohol Treat Q. 1992;9(1):99–105.
76. Machado-Vieira R, Manji HK, Zarate CA. The role of the tripartite glutametergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist. 2009;15(5):525–39.
77. Preskhorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagnosist, CP-101.606, in patients with treatment refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631–7.
78. Sanacora G, Schatzberg AF. Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology. 2015;40(2):259–67.
79. Dutta A, McKie S, Deakin JF. Ketamine and other potential glutamate antidepressants. Psychiatry Res. 2015;225(1–2):1–13.
80. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268–83.
81. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014, 0269881114548296.
82. Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV. Therapeutic infusions of ketamine: do the psychoactive effects matter? Drug Alcohol Depend. 2014;136:153–7.
83. James W. The varieties of religious experience: a study in human nature. Oxford: Oxford World’s Classics; 1907.